Previous Close | 0.4100 |
Open | 0.4798 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 1200 |
Day's Range | 0.3801 - 0.4800 |
52 Week Range | 0.3500 - 300.0000 |
Volume | |
Avg. Volume | 299,257 |
Market Cap | 1.851M |
Beta (5Y Monthly) | 0.78 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -316.5200 |
Earnings Date | May 15, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 252.50 |
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Lin
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company’s on-going collaboration with Vanderbilt Univ
Trial's lower-than-expected event rate suggests improved survival outcomesMINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025. This delay in the projected date for analysis comes as a result of the t